Genomics and Bioinformatics Group web site development and maintenance

我们正在成功地维护和扩展基于Web的Discover工具， 重点是CellMiner和CellMinerCDB。我们的CellMiner“NCI-60分析工具”部分 仍然是药物基因组学整合、研究和发现的重要资源。是 目前是四种工具的宿主，i）“细胞系特征”，ii）“交叉相关”，iii） 模式比较”，和iv）“药物vs基因变体/同种型变体”，所有这些都是 旨在减少科学家整合分子和 药理学数据。我们将继续升级本部分的软件和数据库。 我们目前提供最全面的分子和最大的化合物活性数据集 任何一个大规模的细胞数据库。CellMiner数据和工具正在创建 在合理药物发现、应用和 癌症患者的个体化治疗。由于许多类型的分子改变可以 有助于治疗的结果，基因组和药理学设施（GPF）管理和 以增强理解的方式整合分子和药理学数据， 有助于产生可检验的假设。因此，全球政策框架既提供了获得高 吞吐量数据，并提供软件资源，促进挖掘，理解， and exploitation开发of that data数据.由于DTP药物数据库包含未探索的化合物， 药物，它仍然是一个无与伦比的资源，无论是识别潜在的新药， 提高对已有问题的认识。NCI-60是迄今为止最全面的 任何地方的哺乳动物细胞。CellMiner CDB扩展了这种方法， 附加数据库允许用户随意挖掘和集成。目前，我们的Discover和 CellMiner网站每月有来自90个国家的8,400名个人用户。过去一样 并且目前仍在继续导致转化发现。

We are successfully maintaining and expanding the Discover web-based tools, with emphasis on CellMiner and the CellMinerCDB's. Our CellMiner "NCI-60 Analysis Tools" section remains a significant resource for pharmacogenomic integration, research, and discovery. It is currently the host for four tools, i) "Cell line signature", ii) Cross-correlation", iii) Pattern comparison", and iv) "Drug vs gene variant/isoforms variant", all of which are designed to reduce the time required by the scientist to integrate molecular and pharmacological data. We continue to upgrade both the software and databases in this section. We currently provide the most inclusive set of molecular and largest compound activity data among any of the large-scale cellular databases. The CellMiner data and tools are creating major opportunities for progress in rational drug discovery, application, and individualization of therapy for cancer patients. As molecular alterations of many types can contribute to the outcome of therapy, the Genomic and Pharmacolgy Facility (GPF) manages and integrates molecular and pharmacological data in such a way that enhances understanding, and facilitates the generation of testable hypotheses. The GPF thus both provides access to high throughput data, and provides software resources that facilitate the mining, understanding, and exploitation of that data. As the DTP drug database contains both unexplored compounds and drugs, it remains an unmatched resource both for recognition of potential novel drugs, and improving understanding of pre-existing ones. The NCI-60 is by far the most comprehensively profiled panel of mammalian cells anywhere. CellMiner CDB expands this approach to include addition databases allowing the user to mine and integrate at will. Currently our Discover and CellMiner sites have 8,400 individual users from 90 countries per month. It has in the past and currently continues to lead to translational discoveries.